Carbaglu

Carbaglu is a brand name of carglumic acid, approved by the FDA in the following formulation(s):

CARBAGLU (carglumic acid - tablet; oral)

• 
  Manufacturer: ORPHAN EUROPE
  
  Approval date: March 18, 2010
  
  Strength(s): 200MG ^[RLD]

Has a generic version of Carbaglu been approved?

No. There is currently no therapeutically equivalent version of Carbaglu available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Carbaglu. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Carbaglu.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 18, 2015 - NEW CHEMICAL ENTITY
  
  
  • March 18, 2017 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Carbaglu Consumer Information (Drugs.com)
• Carbaglu Consumer Information (Wolters Kluwer)
• Carbaglu Consumer Information (Cerner Multum)
• Carglumic Acid Consumer Information (Wolters Kluwer)
• Carglumic acid Consumer Information (Cerner Multum)
• Carglumic acid Advanced Consumer Information (Micromedex)